During the last session, Disc Medicine Inc (NASDAQ:IRON)’s traded shares were 0.35 million, with the beta value of the company hitting 0.84. At the end of the trading day, the stock’s price was $42.17, reflecting an intraday gain of 2.84% or $1.17. The 52-week high for the IRON share is $68.73, that puts it down -62.98 from that peak though still a striking 39.2% gain since the share price plummeted to a 52-week low of $25.64. The company’s market capitalization is $1.46B, and the average intraday trading volume over the past 10 days was 0.74 million shares, and the average trade volume was 461.06K shares over the past three months.
Disc Medicine Inc (IRON) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. IRON has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 9 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.07.
Disc Medicine Inc (NASDAQ:IRON) trade information
Disc Medicine Inc (IRON) registered a 2.84% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.84% in intraday trading to $42.17, hitting a weekly high. The stock’s 5-day price performance is 19.68%, and it has moved by -21.54% in 30 days. Based on these gigs, the overall price performance for the year is 40.88%. The short interest in Disc Medicine Inc (NASDAQ:IRON) is 2.42 million shares and it means that shorts have 6.57 day(s) to cover.
The consensus price target of analysts on Wall Street is $89, which implies an increase of 52.62% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $70 and $112 respectively. As a result, IRON is trading at a discount of -165.59% off the target high and -65.99% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.12%. While earnings are projected to return -21.89% in 2025, the next five years will return -1.67% per annum.
IRON Dividends
Disc Medicine Inc is due to release its next quarterly earnings on 2025-Feb-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Disc Medicine Inc (NASDAQ:IRON)’s Major holders
Disc Medicine Inc insiders own 11.32% of total outstanding shares while institutional holders control 79.49%, with the float percentage being 89.63%. PARADIGM BIOCAPITAL ADVISORS LP is the largest shareholder of the company, while 222.0 institutions own stock in it. As of 2024-06-30, the company held over 2.7 million shares (or 10.5451% of all shares), a total value of $121.9 million in shares.
The next largest institutional holding, with 2.51 million shares, is of ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC’s that is approximately 9.7838% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $113.1 million.
Also, the Mutual Funds coming in first place with the largest holdings of Disc Medicine Inc (IRON) shares are Fidelity Select Portfolios-Biotechnology Portfolio and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund. Data provided on Feb 28, 2025 indicates that Fidelity Select Portfolios-Biotechnology Portfolio owns about 883.79 shares. This amounts to just over 2.56 percent of the company’s overall shares, with a $37.26 million market value. The same data shows that the other fund manager holds slightly less at 659.04, or about 1.91% of the stock, which is worth about $27.79 million.
